A Year of Transitions: Navigating the Complex Realities of Biotech, Green Energy, and Global ManufacturingGlobal Report·18 hours agoSAFX-3.44%DHR+0.40%
M&A, Buybacks and C-Suite Shifts: KeyCorp and FactSet Top Estimates as PacBio Slashes OutlookGlobal Report·Aug 18 at 04:43 AMKEY+0.09%ZION-0.44%
PacBio Cuts Outlook as SPRQ-Nx Transition Slows, Targets 2028 Cash-Flow PositivityMarket Beat·Aug 16 at 02:01 AMPACB+18.75%
Niche US Equities See Volatile Q3 With UWM's Historic USD 2 Billion Raise and Sector-Wide AI PivotsGlobal Report·Aug 7 at 04:18 AMUWMC+6.34%ALAR-2.35%
Canaccord Genuity Sticks to Their Buy Rating for Pacific Biosciences (PACB)Tip Ranks·Aug 6 at 06:11 AMPACB+18.75%PIPR-0.08%
Pacific Biosciences of California (NASDAQ:PACB) Announces Quarterly Earnings Results, Misses Estimates By $0.01 EPSMarket Beat·Aug 5 at 05:56 PMPACB+18.75%
PacBio Q2 2026 Earnings: Consumables Growth Could Not Prevent Margin CompressionTradingKey·Aug 5 at 04:11 PMPACB+18.75%
PacBio Q2 FY26 net loss widens to $44.7 million; revenue slips 2% to $39 millionPUBT·Aug 5 at 03:52 PMPACB+18.75%
PacBio Announces Faster Runs, Up to 50% More HiFi Data, and New Compliance Controls for the Vega system | PACB Stock NewsStockTitan·Aug 5 at 12:05 AMPACB+18.75%
